Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

62.34
+0.92501.51%
Volume:368.61K
Turnover:22.94M
Market Cap:35.96B
PE:33.44
High:62.58
Open:61.82
Low:61.82
Close:61.41
52wk High:62.58
52wk Low:34.08
Shares:576.94M
Float Shares:392.53M
Volume Ratio:1.30
T/O Rate:0.09%
Dividend:0.91
Dividend Rate:1.46%
EPS(TTM):1.86
EPS(LYR):1.78
ROE:13.97%
ROA:5.09%
PB:5.26
PE(LYR):34.99

Loading ...

Don't Ignore The Insider Selling In Royalty Pharma

Simply Wall St.
·
Jun 18

Royalty Pharma to join Goldman Sachs Global Healthcare Conference fireside chat

Reuters
·
Jun 05

Royalty Pharma shareholders elect nine directors at annual meeting

Reuters
·
Jun 05

Royalty Pharma CFO Terrance P. Coyne disposes of 64,399 shares worth $3.48 million

Reuters
·
May 29

BRIEF-Royalty Pharma - Enters Revolving Credit Agreement On May 22, 2026

Reuters
·
May 29

Royalty Pharma - Revolving Credit Facility to Mature on May 22, 2031 - SEC Filing

THOMSON REUTERS
·
May 29

Royalty Pharma - Credit Agreement Provides for $1.8 Bln Unsecured Revolving Credit Facility - SEC Filing

THOMSON REUTERS
·
May 29

Royalty Pharma signs USD 1.8 billion revolving credit facility, refinancing 2021 loan agreement

Reuters
·
May 29

How Investors May Respond To Royalty Pharma (RPRX) Strong Q1 Royalties And Expanding Biotech Partnerships

Simply Wall St.
·
May 28

Royalty Pharma EVP Marshall Urist sells 13,684 shares for $721,846.84

Reuters
·
May 22

Royalty Pharma EVP Marshall Urist sells 13,684 shares for $726,150.99

Reuters
·
May 16

Royalty Pharma Director Gregory Norden sells 3,045 shares for $161,385

Reuters
·
May 16

Royalty Pharma to present at BofA Securities Healthcare Conference webcast

Reuters
·
May 08

Royalty Pharma Is Maintained at Buy by Citigroup

Dow Jones
·
May 08

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

TIPRANKS
·
May 07

Royalty Pharma price target raised to $66 from $50 at Citi

TIPRANKS
·
May 07

Royalty Pharma (RPRX) Gets a Buy from TD Cowen

TIPRANKS
·
May 07

Royalty Pharma Q1 Adj. EPS $1.30 Beats $1.21 Estimate, Sales $631.000M Miss $1.235B Estimate

Benzinga Earnings
·
May 06

Royalty Pharma Q1 Net Income, Revenue Rise

MT Newswires Live
·
May 06

Royalty Pharma Q1 adjusted EBITDA climbs 21% to $889 million; portfolio receipts rise 10% to $925 million

Reuters
·
May 06